Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline 4Q

Pharmaceutical sales in the quarter were $9.3 billion (-9%) and $37.7 billion for the year (-2%). Advair sales were $2.8 billion in the quarter (+47%) and $10.8 billion for the year (+54%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 4Q

4Q Revenues: $11.0 billion (-9%)

4Q Earnings: $1.5 billion (-32%)

FY Revenues: $45.1 billion (-1%)

FY Earnings: $8.7 billion (-18%)

Comments: Pharmaceutical sales in the quarter were $9.3 billion (-9%) and $37.7 billion for the year (-2%). Advair sales were $2.8 billion in the quarter (+47%) and $10.8 billion for the year (+54%). Flovent sales were $337 million in the quarter (-5%) and flat at $1.3 billion for the year. Paxil sales were $249 million in the quarter (-19%) and $951 million for the year (-14%). Avandia product sales were $366 million in the quarter (+12%) and $1.5 billion for the year (-17%), due to safety concerns. Lamictal sales were $252 million in the quarter (-59%) and $1.7 billion (-23%). R&D expenses were $2.0 billion in the quarter (-5%) $6.8 billion for the year  (+1%). Restructuring charges for the year included $1.6 billion — compared to $495.3 million FY07 — related to the current operational excellence program and restructuring following the Reliant Pharmaceuticals acquisition. The company’s latest restructuring plan includes a sales force reduction in an effort to focus on growth areas such as vaccines and oncology. Layoff numbers were not announced.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters